Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies
Seasonal influenza is a viral disease caused by influenza virus that spreads easily from person to person. Seasonal influenza is characterized by a sudden onset of high fever, cough (usually dry), headache, muscle and joint pain, severe malaise, sore throat and runny nose. The cough can be severe and last two or more weeks. Most people recover from fever and other symptoms within a week without requiring medical attention. But influenza can cause severe illness or death, especially in people at high risk. Asia-Pacific (APAC) seasonal influenza market is forecast to grow from US$1.24 Billion in 2015 to US$1.71 Billion in 2022, at a compound annual growth rate (CAGR) of 4.7%. The incidence of seasonal influenza is expected to increase significantly across the APAC markets over the forecast period, mainly due to growing elderly populations. Major market drivers are increasing awareness and affordability, rising vaccination coverage in the APAC countries and growing government support for immunization against seasonal influenza.
Marketed seasonal influenza vaccines across the APAC region display various degrees of efficacy in preventing seasonal influenza infection, as well as strong safety profiles. However, the currently available vaccines still display efficacy deficits, particularly in high-risk groups such as the elderly and the immunocompromised. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. APAC region is an attractive market for seasonal influenza vaccine manufacturers. Continuous improvements in the formulation of vaccines has occurred over the years, with the market currently transitioning from trivalent to quadrivalent formulations, which offer protection against an additional B strain of the virus.
The report “Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies” provides an introduction to seasonal influenza, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology, prognosis for patients and detailing the key points driving the seasonal influenza market in the five Asia-Pacific markets: India, China, Australia, South Korea and Japan.
In depth, this report includes the following analysis - - Provides an introduction to seasonal influenza, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology and prognosis for patients. - Provides detailed analysis of the drugs currently marketed for this indication: Fluarix Tetra, FluQuadri, Vaxigrip, Agrippal, Fluad, Fluvax/Afluria, Optaflu, Influvac, GC Flu, Intanza/IDflu, SkyCellflu and Nasovac-S. - Detailed analysis of the pipeline for seasonal influenza, by stage of development, molecule type, program type, mechanism of action and molecular target. - Supplies forecasts for the seasonal influenza market for the 2015–2022 period, including epidemiology, treatment usage patterns, pricing and market size. The five Asia-Pacific markets are covered, and data are presented at a country level. - Provides detailed analysis of key market drivers and barriers for the seasonal influenza market. - Describes the major deals that have taken place in the global seasonal influenza market in recent years. This coverage analyzes licensing and co-development agreements, segmented by stage of development, year, molecule type, mechanism of action and value.
Companies mentioned in this report: AltraVax, Maxygen, Baxter, Takeda, Roche, Savira Pharmaceuticals, Medicago, Philip Morris Products, ContraFect, Trellis, Shionogi.
The seasonal influenza Asia-Pacific market will be valued at $1.71 billion in 2022, growing from $1.24 billion in 2015 at a CAGR of 4.7%. Trivalent and quadrivalent vaccines dominate the seasonal influenza market, but unmet needs exist in terms of safety and efficacy. - Will the drugs under development fulfill the unmet needs of the seasonal influenza market? - Do quadrivalent therapies show continuous growth, and are they facing any competition from trivalent therapies? - How will available therapies be affected by upcoming pipeline therapies? The pipeline contains a range of molecule types and molecular targets, including those that are well established in seasonal influenza. - Which molecular targets appear most frequently in the pipeline? - Will the pipeline drugs fulfill the unmet needs of seasonal influenza market? Market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the emergence of quadrivalent therapies. - How will the annual cost of therapy and market size vary between the five Asia-Pacific markets? Various drivers and barriers will influence the market over the forecast period. - What barriers limit the uptake of premium-priced vaccines in the assessed countries? - What factors are most likely to drive the market in these countries?
Reasons to buy
This report will allow you to - - Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies. - Visualize the composition of the seasonal influenza market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market. - Analyze the seasonal influenza pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. - Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies. - Predict seasonal influenza market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as analysis of the contributions of promising late-stage molecules to market growth. - Identify commercial opportunities in the seasonal influenza deals landscape by analyzing trends in licensing and co-development deals.
Our reports have been used by over 10K customers, including:
Seasonal Influenza: Competitive Landscape to 2026 Summary Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses designated as influenza types A, B, and C.The influenza A H1N1 and H3N2, and influenza B strains are those responsible for seasonal...
Alcoholic Hepatitis Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Alcoholic Hepatitis Global Clinical Trials Review, H2, 2018" provides an overview of Alcoholic Hepatitis clinical trials scenario.This report provides top line data relating to the clinical trials...
Acute Bronchitis Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Acute Bronchitis Global Clinical Trials Review, H2, 2018" provides an overview of Acute Bronchitis clinical trials scenario.This report provides top line data relating to the clinical trials on Acute...
African Trypanosomiasis Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “African Trypanosomiasis Global Clinical Trials Review, H2, 2018" provides an overview of African Trypanosomiasis clinical trials scenario.This report provides top line data relating to the...
Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2018 Summary Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.